aTyr Pharma (LIFE) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- CVS Health plans to split into two public companies by 2028
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
Tweet
Share
E-mailGet Alerts LIFE Hot Sheet
Join SI Premium – FREE
aTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71).
Financial Guidance
As of June 30, 2016, we had $96.6 million in cash, cash equivalents and investments and 23.7 million shares of common stock outstanding.
We currently expect that our cash, cash equivalents and investments will be sufficient to fund our anticipated operations into 2018.
For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber (UBER) Tops Q3 EPS by 2c, Beats on Revenue; Offers Guidance
- Martin Marietta Materials (MLM) Misses Q3 EPS by 70c; offers guidance
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
